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Abstract
Surrogate outcomes are frequently used in cardiovascular disease research. A concern is
that changes in surrogate markers may not reflect changes in disease outcomes. Two recent
clinical trials (Heart and Estrogen/Progestin Replacement Study [HERS], and the
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT])
underscore this problem since their results contradicted what was expected based on the
surrogate outcomes. The current regulatory policy to allow new therapies to be introduced
onto the market based solely on surrogate outcomes may need to be reviewed.
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ALLHAT = Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; CHD = coronary heart disease; CHF = congestive heart
failure; CI = confidence interval; CVD = cardiovascular disease; HERS = Heart and Estrogen/Progestin Replacement Study; MI = myocardial
infarction; RH = relative hazard; SBP = systolic blood pressure.
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Introduction
There has been growing literature in recent years question-
ing the use of surrogate outcomes in medical research
[3–5]. Two major randomized clinical trials, HERS [6] and
ALLHAT [7], have underscored the fallacy of surrogate out-
comes. The first question one must address is: What is a
‘surrogate outcome’? A classic definition is provided by
Temple [8]: “A surrogate endpoint of a clinical trial is a lab-
oratory measurement or a physical sign used as a substi-
tute for a clinically meaningful endpoint that measures
directly how a patient feels, functions or survives. Changes
induced by a therapy on a surrogate endpoint are expected
to reflect changes in a clinically meaningful endpoint.”
However, drugs have multiple effects that are often not
reflected by a surrogate measure, which is especially true
for safety problems. In the HERS [6] study, for instance,
the women receiving the active treatment (estrogen–prog-
estin) had significantly more thromboembolic events than
those patients on placebo (relative hazard [RH] = 2.89,
95% confidence interval [CI] = 1.50–5.58; P = 0.002).
This adverse drug effect is unrelated to the ‘favorable’
hormone effect on lipoprotein levels, generally thought of
as a surrogate for a reduction in coronary events.
Let us consider some of the reasons why surrogates should
or should not be employed in cardiovascular medicine. In ahttp://cvm.controlled-trials.com/content/1/2/076
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perfect world, more information is clearly better than less.
Understanding and measuring the true relationship
between any therapy, on the one hand, and mechanisti-
cally and clinically meaningful endpoints, on the other,
would thus be the natural goal of research. Measuring sur-
rogate outcomes in addition to clinically meaningful end-
points would be quite useful in such studies. Having both
surrogate outcomes and clinically meaningful disease out-
comes measured on the same individuals may allow one
to understand better the underlying pathophysiology.
Why are surrogates used?
So why would one suggest measuring the surrogate
outcome and not the clinically meaningful endpoint?
Some scientists have in recent years argued that the cost
in both time and financial resources may be too great to
conduct research that includes clinically meaningful end-
points. A trial to determine whether a new antihypertensive
agent reduces the risk of mortality would take several
years to perform and cost tens of millions of dollars,
whereas one could determine whether the new drug
lowers elevated blood pressure in several months at the
fraction of the cost. This type of study may also lead to
faster marketing since regulatory approval for many
groups of drugs is currently based on surrogate out-
comes. But is a study based on surrogate outcomes
useful in today’s medical climate? There are currently a
host of antihypertensive drugs shown to lower blood pres-
sure, and some of these improve survival. It is important to
know which drugs provide optimal benefit to the patient.
There are over 100 antihypertensive drugs on the US
market alone today, and clinicians often do not know how
these drugs compare in their ability to prevent disease
outcomes. There is no reason to believe that hypertension
is simply elevated blood pressure. Hypertension is much
more complex. There is also no reason to believe that the
non-blood pressure effects are clinically similar across the
many classes of antihypertensive drugs.
One may thus ask why there is a need to introduce an
additional antihypertensive drug without knowing the
safety and long-term efficacy effects of the drug? For
some diseases, such as cancer, where there are often no
very effective therapies available to patients, there is a
sense of urgency to develop and make new incompletely
tested agents available. For cardiovascular disease, the
sense of urgency is fortunately less pronounced.
The HERS trial
Consider the HERS [6] trial, a multicenter trial conducted
in over 2700 women with coronary disease who were
postmenopausal and younger than 80 years. The trial was
conducted to determine whether a fixed dose of conju-
gated equine estrogen plus medroxyprogesterone acetate
would decrease the rate of occurrence of non-fatal
myocardial infarction or coronary heart disease (CHD)
death when compared with a placebo. Many investigators,
prior to the start of the trial, clearly anticipated that the
patients taking the active treatment would show improved
outcomes. Previous epidemiological research had shown
that women taking estrogen had lower low-density lipopro-
tein cholesterol and higher high-density lipoprotein choles-
terol, and it was hypothesized that this hormone effect on
these surrogate endpoints would result in a reduction in
coronary events. The results of the HERS trial did not
support this hypothesis [6]. Although the women receiving
the active treatment demonstrated an 11% decrease in
low-density lipoprotein and a 10% increase in high-density
lipoprotein cholesterol, both statistically significant
(P < 0.001), the trial found that the treatment and placebo
groups had nearly identical risks for myocardial infarction
(MI) or CHD death (RH = 0.99, 95% CI = 0.80–1.22).
This trial illustrates how information based solely on the
relationship between hormone therapy and the surrogate
endpoints of low-density and high-density lipoprotein cho-
lesterol did not correspond to an expected relationship
between therapy and clinically meaningful endpoints. In
addition, as stated earlier, the number of women in the
active treatment arm with thromboembolic events was sig-
nificantly higher than the number in the placebo group
(RH = 2.89;  P = 0.002). Estrogen may still have a positive
effect on other clinically meaningful endpoints, but more
research clearly ought to be carried out to clarify why
some women appeared to respond unfavorably to
hormone treatment.
The ALLHAT study
A second recent example comes from the ALLHAT study
[7]. This study was a four-armed multicenter trial con-
ducted on more than 44000 patients, of which 15268
patients were randomized to receive chlorthalidone and
9067 to receive doxazosin. The primary outcome of the
study was fatal CHD or non-fatal MI, with secondary out-
comes including all-cause mortality, stroke, and combined
cardiovascular disease (CVD) (CHD death, non-fatal MI,
stroke, angina, coronary revascularization, congestive
heart failure [CHF] and peripheral artery disease). The dif-
ference in systolic blood pressure (SBP) between
chlorthalidone and doxazosin in the ALLHAT study was
2–3 mmHg (with chlorthalidone patients having lower
SBP), while there was no difference in diastolic blood
pressure between the two treatments. The risk of CHF for
the patients on doxazosin, however, was twice that of
patients on chlorthalidone (relative risk = 2.04, 95%
CI = 1.79–2.32). Based on data from the Systolic Hyper-
tension in the Elderly Program [9,10], a 12 mmHg reduc-
tion in SBP was associated with a 49% reduction in CHF
incidence. One could thus infer that the 2–3 mmHg differ-
ence in SBP in ALLHAT between treatments could possi-
bly account for a 10–20% increase in CHF risk, but not a
doubling of risk. These data suggest that chlorthalidone
may have some favorable non-blood pressure effects, thatCurrent Controlled Trials in Cardiovascular Medicine    Vol 1 No 2 D’Agostino Jr
doxazosin may have some unfavorable non-blood pressure
effects or a combination thereof. These results again
demonstrate that measuring the effect of a drug on a sur-
rogate endpoint, such as SBP, does not always provide
adequate information concerning the impact of the drug
on all clinically meaningful endpoints. Both surrogate and
clinically meaningful endpoints were measured in
ALLHAT, allowing information regarding the actions of the
two drugs to be examined and compared. This would not
have been the case had ALLHAT been conducted using
only the surrogate endpoint of blood pressure.
Discussion
So where can surrogate endpoints be used? As already
mentioned, surrogate endpoints are helpful in understand-
ing the mechanism of action for different drugs. Most
drugs generally do not ‘prevent death’ but rather influence
biologic functions that are related to death. Surrogate
endpoints are therefore very useful for advancing scientific
knowledge during the drug development stages. Once a
drug is developed, however, surrogate endpoints should
not to be used for drug approval [3,5], particularly in the
area of cardiovascular disease. The risks of introducing
new incompletely tested drugs usually outweigh the
potential benefits.
But now that we have argued this point, there may be a
new opportunity for surrogate endpoints in future
research, namely genetic studies. The underlying limitation
with the use of surrogate endpoints is that the relationship
between the surrogate endpoint and the clinically mean-
ingful endpoint often is inconsistent or unpredictable. That
is, for some patients lowering of elevated blood pressure
may substantially reduce their risk for a subsequent MI (or
other clinically meaningful endpoints) while for other
patients similar lowering of blood pressure may have little
effect in prognosis. Why this difference? Maybe this could
be genetically determined. That is, there may exist certain
genetic characteristics common to individuals with a
strong causal relationship between blood pressure level
and subsequent MI. If research could accurately identify
and classify individuals into ‘genetic classes’, maybe sur-
rogate endpoints within certain classes could be more
useful in predicting reductions in disease endpoints. Our
knowledge is not yet at this level of sophistication.
Conclusion
In conclusion, the reliance on surrogate endpoints to make
drug approval and treatment decisions can be risky. A
major limitation is safety. Even if we had a perfect surro-
gate for efficacy, it would only be helpful if we also had a
perfect surrogate for safety. There are currently multiple
treatment alternatives available to patients with most car-
diovascular conditions, and the need to introduce new
therapies without strong documentation is not clear. The
pharmaceutical companies have an obligation to provide
physicians and patients with better information about clini-
cal efficacy and safety of new products. The regulatory
agencies ought to consider ‘raising the bar’ for drug
approval to account for these considerations. The lessons
concerning the fallacy of surrogate outcomes continue to
accumulate. The HERS and ALLHAT trials are recent
reminders that theories based on surrogate outcomes
often do not translate to clinically meaningful outcomes.
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